“PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study: Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital ‘Pugliese-Ciaccio’, Catanzaro, Italy” (2025) Confinia Cephalalgica, 35(S1). doi:10.4081/cc.2025.15866.